2024年11月5日 · Introduction: Time-limited ibrutinib plus venetoclax (Ibr+Ven) demonstrated superior PFS, overall survival (OS), and time to next treatment (TTNT) vs chlorambucil plus …

2022年5月13日 · Building on several phase 2 studies in previously untreated and relapsed/refractory CLL, 26-28 the phase 3 GLOW study demonstrated that an all-oral, once …

We summarize 5-year follow-up results from the GLOW trial evaluating the efficacy and safety of first-line fixed-duration ibrutinib plus venetoclax in older adults with untreated CLL/SLL.

2024年9月1日 · GLOW, a phase 3 trial evaluating the efficacy and safety of fixed-duration (FD) I+V in older-adult patients and/or those with comorbidities with previously untreated CLL, …

2023年11月6日 · In the GLOW study, fixed-duration ibrutinib–venetoclax showed superior progression-free survival versus chlorambucil–obinutuzumab in patients with previously …

2024年7月19日 · GLOW trial: A 4-year update on fixed-duration ibrutinib + venetoclax in previously untreated CLL. Here, we summarize the 4-year follow-up data from the phase III …

Background: In the GLOW study, fixed-duration ibrutinib-venetoclax showed superior progression-free survival versus chlorambucil-obinutuzumab in patients with previously untreated chronic …

An extensive cohort study in patients with chronic lymphocytic leukaemia with COVID-19 infection indicates mortality associated with risk factors, such as cardiac failure, a cumulative illness …

2024年3月25日 · GLOW is a randomized, multicenter study conducted across 14 countries in patients with previously untreated CLL. Eligible patients were aged ≥65 years or 18–64 years …

2023年11月2日 · Introduction: In the GLOW trial (NCT03462719), fixed-duration Ibr+Ven treatment has shown superiority to Clb+O in progression-free survival (PFS), better sustained …